{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T09:29:17Z","timestamp":1794475757733,"version":"4.9.1"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T00:00:00Z","timestamp":1776988800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["CVV-450980"],"award-info":[{"award-number":["CVV-450980"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011094","name":"Public Health Agency of Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011094","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012285","name":"BC Children's Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012285","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012395","name":"Canadian Immunization Research Network","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012395","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.vaccine.2026.128630","type":"journal-article","created":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T02:20:08Z","timestamp":1777947608000},"page":"128630","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["mRNA COVID-19 vaccine safety in adults from the Canadian national vaccine safety network"],"prefix":"10.1016","volume":"84","author":[{"given":"Matthew P.","family":"Muller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phyumar","family":"Soe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hennady P.","family":"Shulha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer E.","family":"Isenor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis","family":"Valiquette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manish","family":"Sadarangani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Otto G.","family":"Vanderkooi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James D.","family":"Kellner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karina A.","family":"Top","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaston","family":"De Serres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison","family":"McGeer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marilou","family":"Kiely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly","family":"Marty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike","family":"Irvine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie A.","family":"Bettinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.vaccine.2026.128630_bb0005","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"New England Journal of Medicine."},{"issue":"27","key":"10.1016\/j.vaccine.2026.128630_bb0010","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"New England Journal of Medicine."},{"key":"10.1016\/j.vaccine.2026.128630_bb0015","series-title":"COVID-19 vaccination in Canada","author":"Public Health Agency of Canada","year":"2021"},{"issue":"31","key":"10.1016\/j.vaccine.2026.128630_bb0020","doi-asserted-by":"crossref","first-page":"E1030","DOI":"10.1503\/cmaj.230249","article-title":"The evolution of SARS-CoV-2 seroprevalence in Canada: a time-series study, 2020-2023","volume":"195","author":"Murphy","year":"2023","journal-title":"Can Med Assoc J"},{"issue":"29","key":"10.1016\/j.vaccine.2026.128630_bb0025","doi-asserted-by":"crossref","first-page":"3790","DOI":"10.1016\/j.vaccine.2021.05.087","article-title":"Myocarditis following COVID-19 mRNA vaccination","volume":"39","author":"Abu Mouch","year":"2021","journal-title":"Vaccine"},{"issue":"12","key":"10.1016\/j.vaccine.2026.128630_bb0030","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1056\/NEJMoa2110475","article-title":"Safety of the BNT162b2 mRNA covid-19 vaccine in a nationwide setting","volume":"385","author":"Barda","year":"2021","journal-title":"New England Journal of Medicine."},{"issue":"23","key":"10.1016\/j.vaccine.2026.128630_bb0035","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1056\/NEJMoa2109730","article-title":"Myocarditis after BNT162b2 mRNA vaccine against covid-19 in Israel","volume":"385","author":"Mevorach","year":"2021","journal-title":"New England Journal of Medicine."},{"issue":"4","key":"10.1016\/j.vaccine.2026.128630_bb0040","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1001\/jama.2021.24110","article-title":"Myocarditis cases reported after mRNA-based COVID-19 vaccination in the US from december 2020 to august 2021","volume":"327","author":"Oster","year":"2022","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128630_bb0045","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-051254","article-title":"The Canadian national vaccine safety network: surveillance of adverse events following immunisation among individuals immunised with the COVID-19 vaccine, a cohort study in Canada","volume":"12","author":"Bettinger","year":"2022","journal-title":"BMJ Open"},{"key":"10.1016\/j.vaccine.2026.128630_bb0050","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2024.1385426","article-title":"Impact of recruitment strategies on individual participation practices in the Canadian national vaccine safety network: prospective cohort study","volume":"12","author":"Soe","year":"2024","journal-title":"Front Public Health"},{"key":"10.1016\/j.vaccine.2026.128630_bb0055","series-title":"mRNA COVID-19 vaccine safety among children and adolescents from the Canadian National Vaccine Safety Network Cohort Study. Lancet Reg health am","first-page":"100949","volume":"vol. 40","author":"Soe PV, Otto; Sadarangani, Manish; Naus, Monika; Muller, Matthew;Kellner, James; Top, Karina; Wong, Hubert; Isenor, Jennifer; Marty, Kimberly; Shulha, Hennady;DeSerres, Gaston;Valiquette, Louis; McGeer, Allison; Bettinger, Julie","year":"2024"},{"key":"10.1016\/j.vaccine.2026.128630_bb0060","author":"International Councul for Harmonization of Technical Requirements for Pharmaceutical Use (ICH)"},{"issue":"10","key":"10.1016\/j.vaccine.2026.128630_bb0065","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1016\/j.vaccine.2021.11.074","article-title":"Myocarditis and pericarditis: case definition and guidelines for data collection, analysis, and presentation of immunization safety data","volume":"40","author":"Sexson Tejtel","year":"2022","journal-title":"Vaccine"},{"issue":"11","key":"10.1016\/j.vaccine.2026.128630_bb0075","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1007\/s40264-024-01462-0","article-title":"Acute appendicitis after COVID-19 vaccines in Italy: a self-controlled case series study","volume":"47","author":"Morciano","year":"2024","journal-title":"Drug Saf"},{"issue":"5","key":"10.1016\/j.vaccine.2026.128630_bb0080","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1093\/oxfordjournals.aje.a115734","article-title":"The epidemiology of appendicitis and appendectomy in the United States","volume":"132","author":"Addiss","year":"1990","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.vaccine.2026.128630_bb0085","unstructured":"Anonymous. Trends and levels of the global, regional, and national burden of appendicitis between 1990 and 2021: findings from the global burden of disease study 2021. The lancet Gastroenterology & Hepatology 2024;9(9):825\u2013858, Lancet Gastroenterol Hepatol."},{"key":"10.1016\/j.vaccine.2026.128630_bb0090","article-title":"Surveillance for Adverse Events After COVID-19 mRNA Vaccination","volume":"326(14):1390-1399","author":"Klein","year":"2021","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.vaccine.2026.128630_bb0095","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1001\/jamainternmed.2022.1222","article-title":"Risk of appendicitis after mRNA COVID-19 vaccination in a danish population","volume":"182","author":"Kildegaard","year":"2022","journal-title":"JAMA Intern Med"},{"issue":"3","key":"10.1016\/j.vaccine.2026.128630_bb0100","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1111\/ajt.16517","article-title":"Allergic reactions including anaphylaxis after receipt of the first dose of moderna COVID-19 vaccine - United States, december 21, 2020-January 10, 2021","volume":"21","author":"Shimabukuro","year":"2021","journal-title":"Am J Transplant"},{"issue":"3","key":"10.1016\/j.vaccine.2026.128630_bb0105","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1111\/ajt.16516","article-title":"Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine - United States, december 14-23, 2020","volume":"21","author":"Shimabukuro","year":"2021","journal-title":"Am J Transplant"},{"issue":"8","key":"10.1016\/j.vaccine.2026.128630_bb0110","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1001\/jama.2021.0600","article-title":"Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine","volume":"325","author":"Shimabukuro","year":"2021","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/j.vaccine.2026.128630_bb0115","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1001\/jama.2021.1967","article-title":"Reports of anaphylaxis after receipt of mRNA COVID-19 vaccines in the US-December 14, 2020-January 18, 2021","volume":"325","author":"Shimabukuro","year":"2021","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128630_bb0120","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.vaccine.2021.11.066","article-title":"Anaphylaxis rates associated with COVID-19 vaccines are comparable to those of other vaccines","volume":"40","author":"Maltezou","year":"2022","journal-title":"Vaccine"},{"issue":"11","key":"10.1016\/j.vaccine.2026.128630_bb0125","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1002\/jcph.2120","article-title":"Anaphylaxis and related events following COVID-19 vaccination: a systematic review","volume":"62","author":"Paul","year":"2022","journal-title":"J Clin Pharmacol"},{"issue":"8","key":"10.1016\/j.vaccine.2026.128630_bb0130","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1007\/s10875-022-01350-1","article-title":"Anaphylaxis to SARS-CoV-2 vaccines in the setting of a nationwide passive epidemiological surveillance program","volume":"42","author":"Toledo-Salinas","year":"2022","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.vaccine.2026.128630_bb0135","author":"Johnson","year":"2023"},{"issue":"6","key":"10.1016\/j.vaccine.2026.128630_bb0140","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.18505","article-title":"Epidemiology of myocarditis and pericarditis following mRNA vaccination by vaccine product, schedule, and interdose interval among adolescents and adults in Ontario, Canada","volume":"5","author":"Buchan","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"35","key":"10.1016\/j.vaccine.2026.128630_bb0145","doi-asserted-by":"crossref","first-page":"5153","DOI":"10.1016\/j.vaccine.2022.07.007","article-title":"Risk of myocarditis and pericarditis following BNT162b2 and mRNA-1273 COVID-19 vaccination","volume":"40","author":"Goddard","year":"2022","journal-title":"Vaccine"},{"issue":"23","key":"10.1016\/j.vaccine.2026.128630_bb0150","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1056\/NEJMoa2110737","article-title":"Myocarditis after covid-19 vaccination in a large health care organization","volume":"385","author":"Witberg","year":"2021","journal-title":"New England Journal of Medicine."},{"issue":"7","key":"10.1016\/j.vaccine.2026.128630_bb0155","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S2213-2600(22)00059-5","article-title":"Myopericarditis following COVID-19 vaccination and non-COVID-19 vaccination: a systematic review and meta-analysis","volume":"10","author":"Ling","year":"2022","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.vaccine.2026.128630_bb0160","first-page":"28","article-title":"Myocarditis after BNT162b2 mRNA SARS-CoV-2 vaccine: low incidence and mild severity","volume":"28","author":"Liuzzo","year":"2022","journal-title":"Eur Heart J"},{"issue":"45","key":"10.1016\/j.vaccine.2026.128630_bb0165","doi-asserted-by":"crossref","first-page":"E1529","DOI":"10.1503\/cmaj.220676","article-title":"Observed versus expected rates of myocarditis after SARS-CoV-2 vaccination: a population-based cohort study","volume":"194","author":"Naveed","year":"2022","journal-title":"Can Med Assoc J"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128630_bb0170","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1038\/s41591-021-01630-0","article-title":"Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection","volume":"28","author":"Patone","year":"2022","journal-title":"Nat Med"},{"issue":"6","key":"10.1016\/j.vaccine.2026.128630_bb0175","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/S1473-3099(22)00054-8","article-title":"Safety of mRNA vaccines administered during the initial 6 months of the US COVID-19 vaccination programme: an observational study of reports to the vaccine adverse event reporting system and v-safe","volume":"22","author":"Rosenblum","year":"2022","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"10.1016\/j.vaccine.2026.128630_bb0180","doi-asserted-by":"crossref","first-page":"195","DOI":"10.5694\/mja2.51619","article-title":"The short term safety of COVID-19 vaccines in Australia: AusVaxSafety active surveillance, february - august 2021","volume":"217","author":"Deng","year":"2022","journal-title":"Medical Journal of Australia"},{"issue":"7","key":"10.1016\/j.vaccine.2026.128630_bb0185","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S1473-3099(21)00224-3","article-title":"Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID symptom study app in the UK: a prospective observational study","volume":"21","author":"Menni","year":"2021","journal-title":"Lancet Infect Dis"},{"issue":"9","key":"10.1016\/j.vaccine.2026.128630_bb0190","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1016\/j.vaccine.2024.01.100","article-title":"COVID-19 vaccines and adverse events of special interest: a multinational global vaccine data network (GVDN) cohort study of 99 million vaccinated individuals","volume":"42","author":"Faksova","year":"2024","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X2600438X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X2600438X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T08:59:31Z","timestamp":1794473971000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X2600438X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":37,"alternative-id":["S0264410X2600438X"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128630","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"mRNA COVID-19 vaccine safety in adults from the Canadian national vaccine safety network","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128630","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"128630"}}